Updated Guidelines for the Treatment of Acquired Aplastic Anemia in Children

Area of Science:

• Pediatric Hematology
• Hematopoietic Stem Cell Transplantation
• Aplastic Anemia Management

Background:

• Acquired aplastic anemia (AA) in children requires effective management strategies.
• Hematopoietic stem cell transplantation (HSCT) is a critical treatment option for pediatric AA.
• Previous guidelines require updates based on recent advancements in HSCT.

Purpose of the Study:

• To provide updated management guidelines for pediatric acquired aplastic anemia (AA).
• To emphasize the role and advancements in hematopoietic stem cell transplantation (HSCT) for childhood AA.
• To present an updated treatment algorithm for improved outcomes in pediatric AA.

Main Methods:

• Review of recent literature on pediatric acquired aplastic anemia (AA) management.
• Focus on hematopoietic stem cell transplantation (HSCT) outcomes and donor types.
• Analysis of predictors for response to immunosuppressive therapy (IST).

Main Results:

• Bone marrow transplantation (BMT) from matched or one-locus mismatched related donors (MRD/1MMRD) shows superior failure-free survival compared to IST.
• Absence of minor paroxysmal nocturnal hemoglobinuria clones and short telomere length predict poor IST response.
• Upfront HSCT from matched unrelated donors (MUD) and MRD demonstrate comparable outcomes.
• Unrelated cord blood transplantation (UCBT) and haploidentical HSCT show promising results with effective conditioning regimens.

Conclusions:

• BMT from MRD/1MMRD is the preferred treatment for pediatric AA.
• Upfront MUD BMT is recommended for patients unlikely to respond to IST.
• UCBT and haploidentical HSCT are viable alternative options.
• The updated treatment algorithm aims to enhance outcomes for children with AA.